XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue $ 0 $ 0 $ 1,000,000 $ 0
Operating expenses:        
Research and development 3,224,000 2,824,000 9,312,000 11,457,000
General and administrative 3,282,000 2,544,000 10,976,000 9,338,000
Total operating expenses 6,506,000 5,368,000 20,288,000 20,795,000
Operating loss (6,506,000) (5,368,000) (19,288,000) (20,795,000)
Interest income 504,000 131,000 1,136,000 384,000
Interest expense 0 (4,000) 0 (6,000)
Loss before income taxes and noncontrolling interest (5,840,000) (8,540,000) (18,168,000) (21,525,000)
Income tax provision 0 0 100,000 0
Net loss before noncontrolling interest (5,840,000) (8,540,000) (18,268,000) (21,525,000)
Less: net loss attributable to noncontrolling interest (1,057,000) (1,886,000) (3,440,000) (4,753,000)
Net loss attributable to vTv Therapeutics Inc. (4,783,000) (6,654,000) (14,828,000) (16,772,000)
Net loss attributable to vTv Therapeutics Inc. common shareholders (4,783,000) (6,654,000) (14,828,000) (16,772,000)
Nonrelated Party        
Operating expenses:        
Other income (expense), net 85,000 (3,640,000) 157,000 (1,514,000)
Related Party        
Operating expenses:        
Other income (expense), net $ 77,000 $ 341,000 $ (173,000) $ 406,000
Class A Common Stock        
Operating expenses:        
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) [1] $ (0.88) $ (3.19) $ (2.70) $ (8.04)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) [1] $ (0.88) $ (3.19) $ (2.70) $ (8.04)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) [1] 5,456,307 2,084,973 5,498,479 2,084,973
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) [1] 5,456,307 2,084,973 5,498,479 2,084,973
[1]
(*) Adjusted retroactively for reverse stock split